Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Other Comprehensive Loss [Member]	Total	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
Balance at Dec. 31, 2019	$ 0	$ 0	$ 268	$ 68,578,263	$ (62,694,732)	$ (1,266,555)	$ 4,617,244
Balance (in shares) at Dec. 31, 2019	0	0	2,680,052
Issuance of Series B preferred stock and warrants for cash, conversion of promissory notes, net of offering costs	$ 0	$ 0	$ 0	14,460,155	0	0	14,460,155
Issuance of Series B preferred stock and warrants for cash, conversion of promissory notes, net of offering costs (in shares)	2,912	0	0
Warrants issued in connection with Series B convertible preferred stock private placement	$ 0	$ 0	$ 0	5,952,516	0	0	5,952,516
Warrants issued as inducement to exchange promissory notes into Series B convertible preferred stock private placement	0	0	0	986,526	0	0	986,526
Beneficial conversion feature of Series B and C preferred stock	0	0	0	8,155,212	0	0	8,155,212
Deemed dividend on preferred stock	0	0	0	(8,155,212)	0	0	(8,155,212)
Deemed dividend related to exchange of promissory notes into Series B preferred stock	0	0	0	(1,129,742)	0	0	(1,129,742)
Issuance of Series B preferred PIK shares for accrued dividends	0	$ 0	$ 0	0	0	0	0
Issuance of Series B preferred PIK shares for accrued dividends, shares		0	0					118
Common stock issued upon conversion of Series B preferred stock	$ 0	$ 0	$ 26	(26)	0	0	0
Common stock issued upon conversion of Series B preferred stock (in shares)	(256)	0	256,581
Common stock issued to settle accounts payable	$ 0	$ 0	$ 1	131,136	0	0	131,137
Common stock issued to settle accounts payable (in shares)	0	0	10,594
Common stock issued to consultants	$ 0	$ 0	$ 2	144,403	0	0	144,405
Common stock issued to consultants (in shares)	0	0	18,284
Common stock issued to Lincoln Park for Equity Purchase agreement	$ 0	$ 0	$ 15	988,333	0	0	988,348
Common stock issued to Lincoln Park for Equity Purchase agreement (in shares)	0	0	149,520
Warrants issued in association with convertible debt issuances	$ 0	$ 0	$ 0	1,252,558	0	0	1,252,558
Beneficial conversion feature on convertible debt issuances	0	0	0	1,838,422	0	0	1,838,422
Settlement with former chief executive officer	0	0	0	85,770	0		85,770
Stock-based compensation	0	0	0	549,425	0	0	549,425
Foreign currency translation adjustment	0	0	0	0	0	(154,009)	(154,009)
Net loss	0	0	0	0	(32,671,466)	0	(32,671,466)
Balance at Dec. 31, 2020	$ 0	$ 0	$ 312	93,837,739	(95,366,198)	(1,112,546)	(2,640,693)
Balance (in shares) at Dec. 31, 2020	2,774	0	3,115,031
Issuance of Series C preferred stock and warrants for cash, net of offering costs	$ 0	$ 1	$ 0	7,105,167	0	0	7,105,168
Issuance of Series C preferred stock and warrants for cash, net of offering costs (in shares)	0	10,667	0
Issuance of Series C preferred stock for license acquired	$ 0	$ 1	$ 0	2,467,648	0	0	2,467,649
Issuance of Series C preferred stock for license acquired (in shares)	0	3,290	0
Beneficial conversion feature of Series B and C preferred stock	$ 0	$ 0	$ 0	4,507,125	0	0	4,507,125
Deemed dividend on preferred stock	0	0	0	(4,507,125)	0	0	(4,507,125)
Issuance of Series C preferred stock upon exchange of Series B preferred stock	$ 0	$ 1	$ 0	(1,431)	0	0	(1,430)
Issuance of Series C preferred stock upon exchange of Series B preferred stock (in shares)	(1,839)	19,140	0
Warrants issued in connection with exchange of Series B preferred stock into Series C preferred stock	$ 0	$ 0	$ 0	21,009,683	0	0	21,009,683
Deemed dividend related to exchange of Series B preferred stock into Series C preferred stock	0	0	0	(21,008,253)	0	0	(21,008,253)
Issuance of common stock upon exchange of Series B preferred stock	$ 0	$ 0	$ 3	(3)	0	0	0
Issuance of common stock upon exchange of Series B preferred stock (in shares)	(14)	0	33,500
Common stock issued upon conversion of Series B preferred stock	$ 0	$ 0	$ 26	(26)	0	0	0	$ 14,500,000
Common stock issued upon conversion of Series B preferred stock (in shares)	(259)	0	258,278					1,839.76	19,216.45
Dividends on preferred stock	$ 0	$ 0	$ 0	(465,361)	0	0	(465,361)
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock	$ 0	$ (3)	$ 312	(309)	0	0	0
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock (in shares)	0	(33,097)	3,125,460
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs	$ 0	$ 0	$ 163	14,155,887	0	0	14,156,050
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs (in shares)	0	0	1,625,454
Effect of 10-for-1 reverse stock split	$ 0	$ 0	$ 0	0	0	0	0
Effect of 10-for-1 reverse stock split (in shares)	0	0	(1,706)
Issuance of common stock at-the-market for cash, net of offering costs	$ 0	$ 0	$ 533	18,506,281	0	0	18,506,814
Issuance of common stock at-the-market for cash, net of offering costs (in shares)	0	0	5,333,345
Common stock issued for intellectual property acquired, net	$ 0	$ 0	$ 62	3,999,938	0	0	4,000,000
Common stock issued for intellectual property acquired, net (in shares)	0	0	624,025
Common stock cancelled in connection with acquisition of First Wave Bio, Inc.	$ 0	$ 0	$ (33)	33	0	0	0
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares)	0	0	(332,913)
Common stock issued upon exercise of warrants	$ 0	$ 0	$ 94	4,906,536	0	0	4,906,630
Common stock issued upon exercise of warrants (in shares)	0	0	945,644
Common stock and warrants issued to consultants	$ 0	$ 0	$ 12	1,326,050	0	0	1,326,062
Common stock and warrants issued to consultants (in shares)	0	0	122,230
Settlement with former placement agent	$ 0	$ 0	$ 1	94,498	0	0	94,499
Settlement with former placement agent (in shares)	0	0	7,500
Stock-based compensation	$ 0	$ 0	$ 0	1,371,070	0	0	1,371,070
Foreign currency translation adjustment	0	0	0	0	0	(111,589)	(111,589)
Net loss	0	0	0	0	(58,537,849)	0	(58,537,849)
Balance at Dec. 31, 2021	$ 0	$ 0	$ 1,485	$ 147,305,147	$ (153,904,047)	$ (1,224,135)	$ (7,821,550)
Balance (in shares) at Dec. 31, 2021	662	0	14,855,848